Skip to main content
NCBI home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2023 Jul 20;14:1185122. doi: 10.3389/fphar.2023.1185122

A retrospective study of Reyanning mixture in elderly patients infected with SARS-CoV-2 Omicron variant

Changya Liu 1,†, Xinxin Wu 2,†, Hongqiang Yang 1,†, Xiangru Xu 1, Caiyu Chen 1, Linguangjin Wu 1, Wen Zhang 1, Haimei Shi 1, Yuerong Fei 1, Yuting Sun 1, Hongze Wu 3, Shuang Zhou 4,*, Bangjiang Fang 1,5,*
PMCID: PMC10399593  PMID: 37547325

Abstract

Objective: Reyanning mixture has been demonstrated to be effective in treating infected patients during the outbreak pandemic of SARS-CoV-2 Omicron variant of Coronavirus disease 2019 (COVID-19) in Shanghai 2022. The aim of this study is to further investigate the role of Reyanning mixture specifically in the treatment of elderly patients.

Methods: This study enrolled 1,102 elderly patients who were infected with SARS-CoV-2 Omicron variant. Of these, 291 patients received Reyanning mixture in conjunction with conventional Western medicine treatment were assigned to the treatment group, while 811 patients only received conventional Western medicine treatment were assigned to the control group. Clinical parameters including hospitalization duration, viral shedding time, and Cycle Threshold (Ct) values of novel coronavirus nucleic acid tests, as well as adverse events were recorded and analyzed in both groups.

Results: There was no significant difference in baseline characteristics between two groups. In comparison to the control group, the treatment group demonstrated a substantial difference in hospitalization duration (median: 8 days vs. 10 days, HR: 0.638, 95% CI: 0.558–0.731, p < 0.001). The treatment group also showed a significantly shorter viral shedding time compared to the control group (median: 7 days vs. 8 days, HR: 0.754, 95% CI: 0.659–0.863, p < 0.001). Multivariate Cox proportional-hazards model analysis indicated that the use of Reyanning mixture was closely associated with a reduction in hospitalization duration (HR: 1.562, 95% CI: 1.364–1.789, p < 0.001) and viral shedding time (HR: 1.335, 95% CI: 1.166–1.528, p < 0.001). In addition, during the treatment process, no serious adverse event occurred in either group.

Conclusion: The improvement of clinical parameters in the treatment group indicate a promising therapeutic benefit of Reyanning mixture for elderly patients infected with SARS-CoV-2 Omicron variant in the present study. Further investigations are required to validate this finding by examining the underlying mechanism and function of Reyanning mixture.

Keywords: Reyanning mixture, elderly patients, hospitalization duration, COVID-19, Omicron variant, viral shedding time

Introduction

The outbreak pandemic of COVID-19 has raised significant impact to public health, resulted in widespread suffering across the globe (Teng et al., 2021; Zhang X. et al., 2022; Huang et al., 2022). During this period, vaccines and medications have been developed and implemented to combat the viral infection (Wang Y. et al., 2020; Xu et al., 2022b; Ciotti et al., 2022; Wong et al., 2022), and the SARS-CoV-2 Omicron variant infection appeared to become less virulent. However, the health of elderly people continues to be challenged, as they are more susceptible to severe outcome subsequent to infection (Zhang et al., 2022a), and available data indicated that advanced age and underlying health conditions confer the greatest risk for developing severe COVID-19 infection, which is linked to increased morbidity and mortality rates (Huemer et al., 2021; Ramasamy et al., 2021; Chen et al., 2022; Tong et al., 2022).

Traditional Chinese medicine (TCM) has been widely recognized as medical science with thousands of years, and incorporated as one of the therapeutic options for addressing COVID-19. Despite studies demonstrating the promising therapeutic effects of TCM and integrated traditional Chinese-Western medicine to treat COVID-19 (Yang Y. et al., 2020; Luo et al., 2020; Zhong et al., 2022), there is limited research specifically focus on the elderly patients’ treatment, which is closely associated with reducing the incidence of severe disease and mortality. Reyanning mixture is a Chinese patent medicine, which composed of four botanical drugs: Taraxacum mongolicum Hand.-Mazz. [Asteraceae, Herba taraxaci], Reynoutria japonica Houtt. [Polygonaceae, Polygoni cuspidati rhizoma et radix], Sonchus brachyotus DC. [Asteraceae, Sonchus arenicola Vorosch.], and Scutellaria barbata D.Don [Lamiaceae, Herba scutellariae barbatae], has been recommended in “The Diagnosis and Treatment of New Coronavirus Infected Pneumonia of Shaanxi Province (Trial edition 2)” (Li et al., 2021b). And the efficacy in treating SARS-CoV-2 infection has been illustrated in our previous research (Xu et al., 2023). The objective of the current investigation is to examine the correlation between administration of Reyanning mixture and clinical outcomes among elderly patients.

Methods and materials

Recruitment of participants

All data were obtained from individuals who were hospitalized during the pandemic outbreak in Shanghai 2022. The dataset comprised demographic data, medical history, illness status, hospitalization duration, and results from coronavirus nucleic acid testing. This study was applied in compliance with the tenets of Good Clinical Practice and the Declaration of Helsinki, granted ethical approval by the Medical Ethics Committee (Approval number: JJSZYYY20220403) and was based on the registered clinical trial (ChiCTR2200060292). Informed consent has been collected from all patients.

The diagnostic criteria were applied according to the ninth trial edition guidelines for the diagnosis and treatment of COVID-19 (General Office of National Health Commission of the People’s Republic of China, Office of National Administration of Traditional Chinese Medicine, 2022), as outlined below:

Diagnostic criteria.

  • 1. Presence of relevant epidemiological history.

  • 2. Presence of at least two of the following mentioned clinical symptoms:

    • (i) fever and/or respiratory symptoms, or other clinical manifestations of COVID-19;

    • (ii) imaging features in accordance with COVID-19;

    • (iii) A normal or decreased total white blood cell count as well as lymphocyte count in the early stage of illness.

  • 3. Presented with one of the following microbiological or serological evidence:

    • (i) novel coronavirus nucleic acid detected positively;

    • (ii) positive detection of both IgM and IgG antibodies to novel coronavirus in patients who have not been vaccinated.

Clinical presentations were also assessed according to the guideline criteria (General Office of National Health Commission of the People’s Republic of China, Office of National Administration of Traditional Chinese Medicine, 2022), and an classification of the severity of the illness is presented below.

  • 1. Mild: A mild clinical symptom without image evidence of pneumonia.

  • 2. Common: Clinical manifestations mentioned above, in addition to image evidence of pneumonia.

  • 3. Severe: Individuals who met one or more criteria as follow:

    • (i) Shortness of breath, respiratory rate ≥30 breaths/minute;

    • (ii) Oxygen saturation equal or below to 93% in a resting state;

    • (iii) Arterial partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≤300 mmHg;

    • (iv) Progressive worsening of clinical symptoms and pulmonary imaging showing significant lesion progression >50% within 24–48 h.

  • 4. Critical: Met any condition as follow:

    • (i) Individuals who suffered respiratory failure with requirement of mechanical ventilation;

    • (ii) Shock;

    • (iii) Individuals who suffered multiple organ dysfunction or failure and required intensive care.

We screened the data of all COVID-19 patients who received treatment during hospitalization and finally obtained the cases for this study, based on the criteria as follow:

Inclusion criteria.

  • 1. An individual with an age greater than or equal to 60 years;

  • 2. Patients diagnosed with mild or asymptomatic type of COVID-19 according to the diagnostic criteria;

  • 3. Only received conventional Western medical therapy or combine with Reyanning mixture.

Exclusion criteria.

  • 1. Diagnosed with severe type of COVID-19;

  • 2. Deterioration of clinical symptoms or death within 48 h of admission;

  • 3. Those who were suffering from severe underlying diseases;

  • 4. A severe psychiatric disorder and medication was required;

  • 5. Patient who received other TCM botanical drugs or participated in any other clinical trial beside Reyanning mixture;

  • 6. Received any kind of antiviral, corticosteroid, or monoclonal antibody;

  • 7. Discontinuation, intolerance or refusal to take Reyanning mixture.

The screened and enrolled patients were split into two groups. The treatment group was given Reyanning mixture combine with conventional Western medicine therapy, while the control group received conventional Western medicine based on the Guideline (General Office of National Health Commission of the People’s Republic of China, Office of National Administration of Traditional Chinese Medicine, 2022). Furthermore, all participants were categorized into three subgroups according to their age.

Stratum Ⅰ: Age equal to/greater than 60 years and less than 65 years (≥60 years and <65 years).

Stratum Ⅱ: Age equal to/greater than 65 years and less than 70 years (≥65 years and <70 years).

Stratum Ⅲ: Age equal to/greater than 70 years (≥70 years).

Investigational medications

As a Type A extract (Heinrich et al., 2022), Reyanning mixture was produced by Xingfu Pharmaceutical Group Co., Ltd. (Xi’an, Shaanxi, China), received approval from the National Medical Product Administration of China in 2005 (Approval number: Z20050493), and has been included in the Chinese Pharmacopoeia. According to the Chinese Pharmacopoeia (2020 edition), pharmaceutical manufacturer obtained 372 g Taraxacum mongolicum Hand.-Mazz. (Asteraceae, Herba taraxaci), 372 g Reynoutria japonica Houtt. [Polygonaceae, Polygoni cuspidati rhizoma et radix], 372 g Sonchus brachyotus DC. [Asteraceae, Sonchus arenicola Vorosch.], and 186 g Scutellaria barbata D.Don [Lamiaceae, Herba scutellariae barbatae]. The four botanical drugs mentioned above were decocted twice with water. The first decoction lasted for 2 hrs, and the second for 1 h. The decoction was filtered, concentrated under reduced pressure to an appropriate volume and combined, centrifuged, filtered, and heated to boiling. Finally, 1,000 mL of the decoction was obtained. The quality control analysis of Reyanning mixture used high performance liquid chromatography (HPLC) (Heinrich et al., 2022) has been reported by Su et al. (2021). The primary metabolites of the Reyanning mixture including polydatin, emodin, luteolin, caffeic acid, and chlorogenic acid, have been qualitatively controlled and quantitatively assessed (Su et al., 2021), which were consistent with the Medicine Standards stipulated by the National Medical Products Administration of China.

The active metabolites such as chlorogenic acid, emodin, and caffeic acid, have been studied for their potential antiviral activity against COVID-19 (Adem et al., 2021; Shao et al., 2022; Wang et al., 2022). Polydatin has been found to bind Spike, ACE2, and ACE2, thereby hindering SARS-CoV-2 (Perrella et al., 2021). Moreover, luteolin has been experimentally evaluated against SARS-CoV-2’s RNA-dependent RNA polymerase (Munafò et al., 2022), demonstrating its potential therapeutic effect for COVID-19.

The administration of Reyanning mixture involved oral dosages of 20 mL four times daily, started from the day of enrollment and continued for seven consecutive days. The remaining hospitalization period was followed by standard treatment. A detailed record was kept of the concurrent medications. The hospitalized patients were monitored until discharge, while patients who were discharged within 7 days were subjected to telephone follow-ups to monitor and report any unfavorable incidents. Patients who met the discharge criteria or experienced deterioration of the condition and required hospital transfer were considered to have fulfilled the criteria for study completion.

Evaluation of clinical outcomes

In both groups, pharyngeal swab NATs were performed daily for all the patients. The criteria for discharge was defined according to the Guideline (General Office of National Health Commission of the People’s Republic of China, Office of National Administration of Traditional Chinese Medicine, 2022) as follows: 1) Body temperature maintained normal for at least three consecutive days; 2) Respiratory symptoms improved significantly; 3) Significant improvement in acute infiltrative lesions manifested with pulmonary imaging; 4) Two consecutive COVID-19 nucleic acid tests of N gene and ORF gene with a Ct value of ≥35, or two consecutive negative nucleic acid tests (a minimum sampling interval of 24 h was required).

The primary outcome for this study was hospitalization duration and viral shedding time. The hospitalization duration was measured from admission to the date of discharge. Viral shedding time was measured from the first positive result to the date on which the second consecutive negative nucleic acid test result was obtained. Additionally, the Ct values of the ORF and N genes between two groups were analyzed. The secondary outcome was the evaluation of the overall adverse events, adverse events related to the use of Reyanning mixture, as well as the deterioration of illness during the treatment process. All adverse events that occurred during the treatment process were closely monitored by physicians, while the severity, duration, and onset time were carefully recorded.

Statistical analysis

The analyses of the continuous variables (presented as medians, interquartile ranges) were conducted with the Mann-Whitney U test, while the analyses of categorical variables were conducted with the Chi-square test for counts and percentages (%). Cox proportional-hazards models and 95% confidence intervals (CI) were applied to estimate the variables that may impact the outcome. The Kaplan-Meier method was applied to present the time to events with a 95% CI and generate survival curves.

We used Cox proportional-hazards models to perform sensitivity analysis. Firstly, model 1 was established by adjusting only for age to explore the impact of Reyanning mixture on outcome. Then, model 2 was established by adjusting for patient characteristics listed in our study. Next, we selected cases with restricted age range based on age stratification and re-analyzed the association between Reyanning mixture and outcome. Statistical significance was determined by a p-value less than 0.05 in all tests. Statistical analyses were applied with SPSS (version 26.0; IBM Corp.) and R software (version 4.2.1; R Foundation for Statistical Computing).

Results

Baseline and clinical characteristics

Between April 1 and 31 May 2022, a total of 6,052 patients aged 60 years or older were diagnosed with SARS-CoV-2 Omicron infection and admitted to the N3 Mobile Cabin Hospital at the Shanghai New International Expo Center. Among these patients, 1,102 met the inclusion criteria and were collected in this study. Of these patients, 291 received Reyanning mixture combined with conventional Western medical therapy were assigned to the treatment group, while the remaining 811 patients received only conventional Western medical therapy and served as the control group. Flow chart for screening was present in Figure 1.

FIGURE 1.

FIGURE 1

Open in a new tab

The patient screening flow chart.

In the treatment group, the cohort was comprised of 150 males and 141 females, with a median age of 65 (62, 68) years. The control group consisted of 478 males and 333 females, with a median age of 64 (63, 67) years. No statistically different was observed between two groups. A total of 109 patients (37.5%) in the treatment group and 255 (31.4%) in the control group had underlying medical conditions, including hypertension, diabetes, cerebrovascular diseases, and cardiovascular diseases, et al., and there was no statistically significant difference between the two groups (p = 0.061). Patients in both groups presented with various clinical syndromes. The most common symptoms of hospitalization included cough, sputum, sore throat, fever, muscle soreness, and fatigue. Regarding vaccination status, 92 patients were unvaccinated, 7 patients were partially vaccinated, 75 received fully dose and 117 received booster within treatment group. In the control group, 235 patients were unvaccinated, 14 had received one dose, 235 had received two doses, and 327 had received a booster. The baseline information of two groups were presented in Table 1.

TABLE 1.

Baseline information of Treatment group and Control group.

Treatment group (n = 291) Control group (n = 811) p-value
Gender n (%)
Female 141 (48.5%) 333 (41.1%) 0.985
Age, median (interquartile ranges) 65 (62, 68) 64 (63, 67) 0.453
Underlying diseases n (%) 109 (37.5%) 255 (31.4%) 0.061
Vaccination status n (%) 0.614
Unvaccinated 92 (31.6%) 235 (28.9%)
Partially vaccinated 7 (2.4%) 14 (1.7%)
Full vaccination 75 (25.8%) 235 (28.9%)
Booster 117 (40.2%) 327 (40.3%)
Type 0.108
Mild 228 (78.4%) 670 (82.6%)
Asymptomatic 63 (21.6%) 141 (17.4%)
Clinical symptoms n (%)
Cough 182 (62.5%) 533 (65.7%) 0.330
Sputum 51 (17.6%) 161 (19.9%) 0.388
Sore throat 52 (17.9%) 108 (13.3%) 0.059
Fever 97 (33.3%) 226 (27.9%) 0.079
Muscle soreness 63 (21.6%) 161 (19.9%) 0.513
Fatigue 42 (14.4%) 103 (12.7%) 0.453
Shortness of breath 7 (2.4%) 18 (2.2%) 0.855
Apocleisis 8 (2.7%) 20 (2.5%) 0.792
Open in a new tab

Primary outcome

The hospitalization duration in the treatment group and the control group were 8 (4, 11) days and 10 (8, 12) days, respectively. Furthermore, the viral shedding time was 7 (3, 10) days in the treatment group and 8 (6, 10) days in the control group, as illustrated in Figure 2. The Kaplan-Meier graph indicated a significant reduction in both hospitalization time and virus clearance time for the treatment group compared to the control group (HR: 0.638, 95% CI: 0.558-0.731, p < 0.001; HR: 0.754, 95% CI: 0.659-0.863, p < 0.001, respectively) (Figures 3, 4). Furthermore, we collected and analyzed the nucleic acid test results of patients during their hospitalization for a period of 10 days. Both groups of patients exhibited an upward trend in Ct values of the open reading frame (ORF) and nucleocapsid (N) genes after receiving treatment. Comparison with the control group, the results revealed that patients who received treatment with Reyanning mixture exhibited a more pronounced upward trend in Ct values (Figure 5; Table 2).

FIGURE 2.

FIGURE 2

Open in a new tab

Comparison of hospitalization duration and viral shedding time between Treatment group and Control group. (A) represented the comparison of hospitalization duration between two groups. (B) represented the comparison of viral shedding time between two groups.

FIGURE 3.

FIGURE 3

Open in a new tab

The Kaplan-Meier gram for the hospitalization duration between Treatment group and Control group. HR, hazard ratio.

FIGURE 4.

FIGURE 4

Open in a new tab

The Kaplan-Meier gram for the viral shedding time between Treatment group and Control group. HR, hazard ratio.

FIGURE 5.

FIGURE 5

Open in a new tab

Variation of Ct values of the ORF (A) and N (B) genes.

TABLE 2.

Comparison of the ORF/N genes Ct values between the Treatment group and Control group.

Day ORF gene p-value N gene p-value
Treatment group Control group Treatment group Control group
1 30.56 ± 7.48 30.28 ± 5.99 0.579 30.07 ± 7.87 29.73 ± 5.69 0.515
2 31.91 ± 6.99 32.71 ± 5.35 0.094 31.40 ± 7.46 32.36 ± 5.57 0.057
3 32.51 ± 6.62 33.35 ± 4.64 0.066 32.04 ± 7.11 33.29 ± 4.86 0.001
4 32.36 ± 5.97 33.85 ± 4.39 0.001 31.79 ± 6.29 33.56 ± 4.57 0.001
5 33.24 ± 5.62 34.41 ± 4.18 0.001 32.63 ± 5.89 34.48 ± 4.49 0.001
6 34.87 ± 5.17 34.89 ± 3.82 0.955 34.48 ± 5.59 34.75 ± 3.94 0.593
7 35.89 ± 4.45 34.84 ± 3.58 0.020 35.42 ± 4.88 34.61 ± 3.74 0.112
8 37.35 ± 3.28 35.10 ± 3.58 0.001 37.06 ± 3.91 34.77 ± 3.63 0.001
9 38.50 ± 2.36 36.02 ± 2.95 0.001 38.30 ± 2.97 35.80 ± 3.19 0.001
10 38.92 ± 1.73 36.14 ± 2.49 0.001 38.79 ± 2.64 36.03 ± 2.63 0.001
Open in a new tab

The variables of all enrolled patients that may impact hospitalization duration and viral shedding time, including age, gender, disease type, underlying condition, vaccination status, and use of Reyanning mixture, were incorporated into a Cox proportional-hazards model (presented in Table 3), which revealed a significant association between age, vaccination status, the use of Reyanning mixture with hospitalization duration, as well as viral shedding time (p < 0.05). After adjustment for age and vaccination status in the multivariate regression analysis, the result suggested that use of Reyanning mixture significantly benefitted the reduction of both hospitalization duration and viral shedding time (HR: 1.562, 95% CI: 1.364-1.789, p < 0.001; HR: 1.335, 95% CI: 1.166-1.528, p < 0.001, respectively).

TABLE 3.

Cox proportional-hazards model for hospitalization duration and viral shedding time.

Hospitalization duration Viral shedding time
Univariate Multivariate Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age 0.962 (0.945, 0.980) <0.001 0.963 (0.946, 0.981) <0.001 0.962 (0.945, 0.980) <0.001 0.964 (0.947, 0.982) <0.001
Gender 1.026 (0.911, 1.154) 0.676 0.997 (0.884, 1.126) 0.967 1.045 (0.928, 1.177) 0.465 1.010 (0.895, 1.140) 0.867
Type 1.116 (0.958, 1.299) 0.159 1.146 (0.980, 1.339) 0.088 1.104 (0.948, 1.285) 0.204 1.121 (0.959, 1.310) 0.152
Underlying diseases 1.008 (0.889, 1.143) 0.902 0.948 (0.833, 1.079) 0.417 1.019 (0.899, 1.155) 0.770 0.965 (0.848, 1.098) 0.589
Vaccination status 1.205 (1.059, 1.373) 0.005 1.205 (1.057, 1.373) 0.005 1.189 (1.045, 1.354) 0.009 1.180 (1.035, 1.344) 0.013
Group 1.520 (1.329, 1.740) <0.001 1.562 (1.364, 1.789) <0.001 1.307 (1.142, 1.495) <0.001 1.335 (1.166, 1.528) <0.001
Open in a new tab

CI, confidence interval; HR, hazard ratio.

In the sensitivity analysis, firstly, we used hospitalization duration as the dependent variable, while group and age as independent variables, and fitted in the Cox proportional-hazards model 1. The result showed a statistical significance, with a β value of 0.433. Then, we included group, age, gender, vaccination status, underlying diseases, and disease type as independent variables and fitted in the Cox proportional-hazards model 2. The result showed a β value of 0.446, with p < 0.001, which was consistent with model 1. Similarly, we applied the above method to analyze the association between group and viral shedding time, and the results showed a β value of 0.276 and 0.289, with p < 0.001 respectively. The sensitivity analysis manifested the association between the use of Reyanning mixture and outcome was consistent with our main finding (Supplementary Table S1).

Furthermore, we included cases within the age range specified for each subgroup based on the age stratification, conducted independent analysis with multivariate Cox proportional-hazards model and presented in Table 4 to estimate the impact of using Reyanning mixture on the hospitalization duration and viral shedding time. The result still exhibited a significant association between the use of Reyanning mixture and hospitalization duration (HR: 1.844, 95% CI: 1.455-2.338, p < 0.001; HR: 1.590, 95% CI: 1.268-1.993, p < 0.001; HR: 1.788, 95% CI: 1.201-2.663, p < 0.05, respectively) as well as viral shedding time (HR: 1.547, 95% CI: 1.220-1.961, p < 0.001; HR: 1.349, 95% CI: 1.075-1.691, p < 0.05; HR: 1.534, 95% CI: 1.035-2.274, p < 0.05, respectively) in different age stratums.

TABLE 4.

Cox proportional-hazards model for estimating the impact of using Reyanning mixture on the hospitalization duration and viral shedding time in different age stratums.

Hospitalization duration Viral shedding time
Univariate Multivariate Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
60–64 years 1.647 (1.352, 2.005) <0.001 1.844 (1.455, 2.338) <0.001 1.395 (1.146, 1.698) 0.001 1.547 (1.220, 1.961) <0.001
65–69 years 1.587 (1.272, 1.981) <0.001 1.590 (1.268, 1.993) <0.001 1.359 (1.090, 1.695) 0.006 1.349 (1.075, 1.691) 0.010
≥70 years 1.771 (1.198, 2.617) 0.004 1.788 (1.201, 2.663) 0.004 1.583 (1.074, 2.332) 0.020 1.534 (1.035, 2.274) 0.033
Open in a new tab

CI, confidence interval; HR, hazard ratio.

Secondary outcome

Throughout the treatment process, the most frequently observed adverse events included diarrhea, muscle soreness, and insomnia in both groups (Table 5). No severity adverse event was observed in our series. In addition, no progressive deterioration or death was occurred in the treatment period of our series. Besides, six patients in the treatment group were experienced with slight diarrhea, which was considered as a possible association with Reyanning mixture use. After symptomatic treatment, all adverse events were alleviated.

TABLE 5.

Adverse events in the Treatment group and Control group.

Adverse events Treatment group Control group p-value
Diarrhea 12 (4.1%) 36 (4.4%) 0.821
Muscle soreness 10 (3.4%) 32 (3.9%) 0.697
Headache 3 (1.0%) 10 (1.2%) 0.784
Insomnia 20 (3.8%) 33 (4.0%) 0.055
Dizziness 4 (1.3%) 9 (1.1%) 0.720
Palpitation 2 (0.7%) 5 (0.6%) 0.896
Stomachache 5 (1.7%) 12 (1.5%) 0.777
Open in a new tab

Discussion

In the present study, we analyzed the data of 1,102 elderly patients from our ward, infected with SARS-CoV-2 Omicron variant. Our findings revealed a strong correlation between the length of hospitalization and viral shedding time in elderly patients, and various factors including age, vaccination status, and the use of Reyanning mixture. Compared to the control group, the use of Reyanning mixture significantly reduced hospitalization duration and viral shedding time in elderly individuals. Additionally, our study analyzed the patients in different age stratums still manifested a reduction in hospitalization duration and viral clearance time with Reyanning mixture treatment. Furthermore, there was no significant adverse event observed during the use of Reyanning mixture, nor any deterioration of the health condition. These results suggested that Reyanning mixture was an effective and safe treatment for elderly patients with COVID-19.

Since the initial emergence of COVID-19 pandemic in late 2019, multiple variants of SARS-CoV-2 have been identified. In addition to respiratory symptoms, infection can also trigger a cytokine storm, lead to systemic inflammation and damage to multiple organs. The Omicron variant, designated B.1.1.529, was a heavily mutated strain which was deemed a matter of concern on 26 November 2021 by the World Health Organization, posed a high infection risk with serious repercussions (Araf et al., 2022). Despite significant progress in clinical diagnosis and treatment, there were still many uncertainties in the therapy for this variation, and the long-term protection efficacy of current vaccines against viral variants still remained controversies, especially for elderly patients (Meo et al., 2021). In addition, the variant Omicron has been recognized cause more infectious, medical system overload and exhaust, with continuous outbreaks (Shen et al., 2022).

In addition to conventional clinical treatment, a range of initiatives, such as clinical trials and observation, have been undertaken to discover the utility of TCM for COVID-19, especially for those with antiviral and anti-inflammatory properties (Zhang et al., 2022b; Guo et al., 2022), to find alternative approaches to managing the disease course. Furthermore, various botanical drugs, such as Xuebijing injection, Qingfei Paidu decoction, and Lianhua Qingwen capsule, have been investigated in this regard and provided evidences in treating with COVID-19 infection (Li et al., 2021a; Hu et al., 2021; Tianyu and Liying, 2021). Shi J. et al. (2020) performed a retrospective analysis of data from 234 patients diagnosed with COVID-19. The results revealed that patients who received TCM treatment within 3 days of hospital admission exhibited a significant reduction in hospitalization duration, disease course, and nucleic acid negative conversion time, compared to those who received TCM decoction after 7 days or more. Hu et al. (2021) reported that the application of Lianhua Qingwen capsule manifested a significantly increasing in the recovery rate, with shorting the median time of symptom recovery in their study. Zhang et al. (2021) conducted an evaluation of 25 patients diagnosed with mild or common COVID-19 who received treatment with Tanreqing capsule. The result indicated a significant reduction in negative conversion time compared to the group that received conventional Western medicine. Shi N. et al. (2020) reported a series of 782 patients with confirmed COVID-19 and treated with Qingfei Paidu decoction, investigated the association between recovery and the treatment initiation time among infected individuals. However, there is a scarcity of research specifically targeting the application of TCM in treating elderly patients with SARS-CoV-2 infection, which remains an important area of study that requires further research.

The Reyanning mixture has been authorized by the National Medical Products Administration of China, in which consists four kind of herbs with a 2:2:2:1 proportion by weight. Previous studies has shown the usage of Reyanning mixture in treating infectious diseases such as fever, pneumonia, tonsillitis suppurative, sore throat, acute pharyngitis, and acute bronchitis (Lyu et al., 2020; Lyu et al., 2022). In a clinical investigation conducted by Yang M. et al. (2020), a series of 49 patients diagnosed with common COVID-19 were enrolled. The administration of Reyanning mixture was found to significantly ameliorate the clinical symptoms and chest images from computed tomography of the COVID-19 patients. However, the study did not specifically examine the correlation between the use of Reyanning mixture and the hospitalization duration or nucleic acid conversion time in elderly patients. Additionally, it should be noted that the sample size was relatively small, with only 26 cases receiving Reyanning mixture. In terms of the botanical drug mechanisms, Bao et al. (2020) assessed the efficacy of Reyanning mixture in a mouse model that was designed to mimic the syndrome of human coronavirus pneumonia. The results demonstrated the effectiveness of Reyanning mixture in the improvement of lung lesions, autoimmune function, enhancing gastro-intestinal function, as well as reducing the expression of inflammatory factors. Han et al. (2021) used the network pharmacology approach, exhibited its anti-inflammation effects via regulating the cell proliferation, and the surviving pathways. Wang M. et al. (2020) employed network pharmacology in addition to molecular docking methodologies and forecast the potential application of Reyanning mixture in treating COVID-19. Their findings suggested that the active constituents of Reyanning mixture may exert their therapeutic effects by modulating various targets, including CD40LG, IL2, IL6, IL10, and CXCL10, CXCL8. Nonetheless, it should be noted that the studies still lacked sufficient experimental validation through in vivo and in vitro assessments.

Recently, we conducted a randomized controlled study comprising of 2,830 patients, and the result indicated that Reyanning mixture represented a safe and effective treatment option for promoting recovery from asymptomatic and mild SARS-CoV-2 Omicron infection, as well as accelerating virus clearance (Xu et al., 2023). As the result of current study, we provided further evidence for the conversion to negative nucleic acid status, as well as a potential efficacious option of TCM for treating COVID-19 in elderly patients. Based on another study we conducted previously (Xu et al., 2022a), the finding indicated that elderly patients had prolonged hospitalization duration and a higher risk of deterioration. Additionally, we observed a correlation between the appliance of TCM and a reduction in hospitalization duration. An earlier study has identified age as an independent risk factor that may prolong the time of viral clearance (Wang K. et al., 2020). Moreover, some scholars have suggested that prolonged viral shedding time may be primarily associated with chronic diseases and low immunity (Hao et al., 2020), which were more prevalent among elderly patients. The result of our present study demonstrated that, in comparison to the control group, a significant reduction in hospitalization time and viral clearance time was observed in the population receiving Reyanning mixture, which could provide potential advantage for COVID-19 treatment in elderly patients.

Our finding provided another evidence of Reyanning mixture and treatment option for elderly patients infected with SARS-CoV-2 Omicron variant. Nonetheless, the study had certain limitations that should not be neglected. Firstly, as a retrospective and observational investigation, it may be subject to inherent biases. Secondly, the research exclusively focused on patients with the Omicron variant in Shanghai, which may restrict the generalizability of the findings. Moreover, the study was restricted in specific population, and the use of conventional Western medicine in the treatment regimen may have confounded the result and introduced potential bias.

In conclusion, given the circumstance of elderly patient, how to respond to SARS-CoV-2 infection and protect the health condition of this population still requires attention and concern. The present finding suggested that Reyanning mixture was a safe and effective treatment option for our series, and provided evidence for the application of Reyanning mixture in the elderly population. Prospective clinical trials with larger sample, targeting specific population, and incorporating more indicators for monitoring and analyzing are needed, and further exploration should be conducted to reveal the underlying mechanism and function of Reyanning mixture.

Acknowledgments

We express our gratitude to the Jiangxi Medical Team for their support in Shanghai and their significant contributions to the fight against the epidemic. We extend our appreciation to the medical personnel at Jiujiang Hospital of Traditional Chinese Medicine and Longhua Hospital for their assistance with coordination and data management throughout this study.

Funding Statement

This study was supported by the Emergency research project of World Federation of Chinese Medicine Societies (SZL-2022YI010).

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of Jiujiang Hospital of Traditional Chinese Medicine. The patients/participants provided their written informed consent to participate in this study.

Author contributions

Conception and design: CL, BF, and SZ. Analysis and interpretation of the data: CL and XW. Drafted the article: CL and XW. Critically revised the article: YF and YS. Reviewed submitted version of manuscript: CL, BF, and SZ. Final approval of the version to be published: BF and SZ. Statistical analysis: XW, WZ, and LW. Administrative, data collection: HW, CC, HY, and HS. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.1185122/full#supplementary-material

Click here for additional data file. (1.7MB, docx)

Abbreviations

TCM, Traditional Chinese medicine; COVID-19, Coronavirus disease 2019; HR, Hazard ratio; CI, Confidence interval; Ct, Cycle Threshold; HPLC, High performance liquid chromatography; ORF, Open reading frame; N, Nucleocapsid.

References

  1. Adem Ş., Eyupoglu V., Sarfraz I., Rasul A., Zahoor A. F., Ali M., et al. (2021). Caffeic acid derivatives (CAFDs) as inhibitors of SARS-CoV-2: CAFDs-based functional foods as a potential alternative approach to combat COVID-19. Phytomedicine 85, 153310. 10.1016/j.phymed.2020.153310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Araf Y., Akter F., Tang Y. D., Fatemi R., Parvez M. S. A., Zheng C., et al. (2022). Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J. Med. Virol. 94, 1825–1832. 10.1002/jmv.27588 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bao L., Shi Y. J., Geng Z. H., Sun J., Zhao R. H., Du C. Q., et al. (2020). Application of Reyanning Mixture in evaluating combining disease with syndrome of human coronavirus pneumonia with pestilence attacking lung syndrome. Zhongguo Zhong Yao Za Zhi 45, 1465–1472. 10.19540/j.cnki.cjcmm.20200303.401 [DOI] [PubMed] [Google Scholar]
  4. Chen J., Wang R., Gilby N. B., Wei G. W. (2022). Omicron variant (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. J. Chem. Inf. Model 62, 412–422. 10.1021/acs.jcim.1c01451 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ciotti M., Ciccozzi M., Pieri M., Bernardini S. (2022). The COVID-19 pandemic: Viral variants and vaccine efficacy. Crit. Rev. Clin. Lab. Sci. 59, 66–75. 10.1080/10408363.2021.1979462 [DOI] [PubMed] [Google Scholar]
  6. General Office of National Health Commission of the People’s Republic of China, Office of National Administration of Traditional Chinese Medicine (2022). Diagnosis and treatment of corona virus disease-19 (9th trial edition). China Medicine 17, 481–487. [Google Scholar]
  7. Guo J., Qin Z., Lau N. C., Fong T. L., Meng W., Zhang Z. J., et al. (2022). Chinese medicine for coronavirus disease 2019 (COVID-19): A GRADE-assessed systematic review and meta-analysis. Am. J. Chin. Med. 50, 1–31. 10.1142/s0192415x2250001x [DOI] [PubMed] [Google Scholar]
  8. Han L., Kou J., Hu K., Wang Y., Tang Z., Wu Z., et al. (2021). Protective effects of Re-yan-ning mixture on Streptococcus pneumonia in rats based on network pharmacology. Pharm. Biol. 59, 209–221. 10.1080/13880209.2021.1872653 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hao S., Lian J., Lu Y., Jia H., Hu J., Yu G., et al. (2020). Decreased B cells on admission associated with prolonged viral RNA shedding from the respiratory tract in coronavirus disease 2019: A case-control study. J. Infect. Dis. 222, 367–371. 10.1093/infdis/jiaa311 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Heinrich M., Jalil B., Abdel-Tawab M., Echeverria J., Kulić Ž., Mcgaw L. J., et al. (2022). Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research-The ConPhyMP-Guidelines. Front. Pharmacol. 13, 953205. 10.3389/fphar.2022.953205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hu K., Guan W. J., Bi Y., Zhang W., Li L., Zhang B., et al. (2021). Efficacy and safety of lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine 85, 153242. 10.1016/j.phymed.2020.153242 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Huang W., Jiang B., Luo J., Luo M., Ding X., Yang Q., et al. (2022). Treatment of COVID-19 in hemodialysis patients using traditional Chinese medicine: A single-center, retrospective study. Front. Pharmacol. 13, 764305. 10.3389/fphar.2022.764305 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Huemer F., Rinnerthaler G., Jörg B., Morre P., Stegbuchner B., Proksch E., et al. (2021). Results of a hospitalization policy of asymptomatic and pre-symptomatic COVID-19-positive long-term care facility residents in the province of Salzburg-a report from the AGMT COVID-19 Registry. Geroscience 43, 1877–1897. 10.1007/s11357-021-00352-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Li Y., Li B., Wang P., Wang Q. (2021a). Traditional Chinese medicine, Qingfei Paidu decoction and xuanfei baidu decoction, inhibited cytokine production via NF-κB signaling pathway in macrophages: Implications for coronavirus disease 2019 (COVID-19) therapy. Front. Pharmacol. 12, 722126. 10.3389/fphar.2021.722126 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Li Y., Zhang J., Li S., Li F., Zhao C., Li F., et al. (2021b). Efficacy and safety of reyanning mixture combined with conventional western medicine for treating COVID-19: A protocol for systematic review and meta-analysis. Med. Baltim. 100, e24169. 10.1097/MD.0000000000024169 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Luo E., Zhang D., Luo H., Liu B., Zhao K., Zhao Y., et al. (2020). Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): An empirical study from wuhan, hubei province, China. Chin. Med. 15, 34. 10.1186/s13020-020-00317-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lyu J., Wang Z. F., Xie Y. M., Cheng F. J., Zhang Q., Cui X. (2022). Clinical comprehensive evaluation of Reyanning Mixture in treatment of acute upper respiratory tract infection (heat-toxin attacking lung syndrome). Zhongguo Zhong Yao Za Zhi 47, 1476–1483. 10.19540/j.cnki.cjcmm.20211206.501 [DOI] [PubMed] [Google Scholar]
  18. Lyu J., Yang C., Wang L. X., Xie Y. M., Yu X. Q., Gu L., et al. (2020). Randomized double-blind parallel controlled multicenter trial of Reyanning Mixture in treatment of acute tonsillitis. Zhongguo Zhong Yao Za Zhi 45, 3282–3291. 10.19540/j.cnki.cjcmm.20200420.501 [DOI] [PubMed] [Google Scholar]
  19. Meo S. A., Bukhari I. A., Akram J., Meo A. S., Klonoff D. C. (2021). COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of pfizer/BioNTech and moderna vaccines. Eur. Rev. Med. Pharmacol. Sci. 25, 1663–1669. 10.26355/eurrev_202102_24877 [DOI] [PubMed] [Google Scholar]
  20. Munafò F., Donati E., Brindani N., Ottonello G., Armirotti A., De Vivo M. (2022). Quercetin and luteolin are single-digit micromolar inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase. Sci. Rep. 12, 10571. 10.1038/s41598-022-14664-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Perrella F., Coppola F., Petrone A., Platella C., Montesarchio D., Stringaro A., et al. (2021). Interference of polydatin/resveratrol in the ACE2:spike recognition during COVID-19 infection. A focus on their potential mechanism of action through computational and biochemical assays. Biomolecules 11, 1048. 10.3390/biom11071048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ramasamy M. N., Minassian A. M., Ewer K. J., Flaxman A. L., Folegatti P. M., Owens D. R., et al. (2021). Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet 396, 1979–1993. 10.1016/S0140-6736(20)32466-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Shao Q., Liu T., Wang W., Liu T., Jin X., Chen Z. (2022). Promising role of emodin as therapeutics to against viral infections. Front. Pharmacol. 13, 902626. 10.3389/fphar.2022.902626 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shen Y., Ai J., Lin N., Zhang H., Li Y., Wang H., et al. (2022). An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants. Emerg. Microbes Infect. 11, 1518–1523. 10.1080/22221751.2022.2078230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Shi J., Lu Y., Zhang Y., Xia L., Ye C., Lü Y., et al. (2020a). Traditional Chinese medicine formulation therapy in the treatment of coronavirus disease 2019 (COVID-19). Am. J. Chin. Med. 48, 1523–1538. 10.1142/S0192415X20500755 [DOI] [PubMed] [Google Scholar]
  26. Shi N., Liu B., Liang N., Ma Y., Ge Y., Yi H., et al. (2020b). Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study. Pharmacol. Res. 161, 105290. 10.1016/j.phrs.2020.105290 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Su Y., Liu H., Du X., Zhang X., Zhang X. (2021). Health-related quality of life in Chinese workers: A systematic review and meta-analysis. Mod. Tradit. Chin. Med. 41, 29–33. 10.1186/s41256-021-00209-z [DOI] [Google Scholar]
  28. Teng S., Sobitan A., Rhoades R., Liu D., Tang Q. (2021). Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity. Brief. Bioinform 22, 1239–1253. 10.1093/bib/bbaa233 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Tianyu Z., Liying G. (2021). Identifying the molecular targets and mechanisms of xuebijing injection for the treatment of COVID-19 via network parmacology and molecular docking. Bioengineered 12, 2274–2287. 10.1080/21655979.2021.1933301 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Tong X., Huang Z., Zhang X., Si G., Lu H., Zhang W., et al. (2022). Old age is an independent risk factor for pneumonia development in patients with SARS-CoV-2 omicron variant infection and a history of inactivated vaccine injection. Infect. Drug Resist 15, 5567–5573. 10.2147/IDR.S380005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Wang K., Zhang X., Sun J., Ye J., Wang F., Hua J., et al. (2020a). Differences of severe acute respiratory syndrome coronavirus 2 shedding duration in sputum and nasopharyngeal swab specimens among adult inpatients with coronavirus disease 2019. Chest 158, 1876–1884. 10.1016/j.chest.2020.06.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wang M., Tang Z., Liu Y., Song Z., Zhou R., Xu H., et al. (2020b). Uraemia disarms neutrophils against Candida. Mod. Chin. Med. 22, 484–491. 10.1038/s41581-020-0322-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wang W. X., Zhang Y. R., Luo S. Y., Zhang Y. S., Zhang Y., Tang C. (2022). Chlorogenic acid, a natural product as potential inhibitor of COVID-19: Virtual screening experiment based on network pharmacology and molecular docking. Nat. Prod. Res. 36, 2580–2584. 10.1080/14786419.2021.1904923 [DOI] [PubMed] [Google Scholar]
  34. Wang Y., Zhang D., Du G., Du R., Zhao J., Jin Y., et al. (2020c). Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569–1578. 10.1016/S0140-6736(20)31022-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wong C. K. H., Au I. C. H., Lau K. T. K., Lau E. H. Y., Cowling B. J., Leung G. M. (2022). Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: An observational study. Lancet Infect. Dis. 400, 1213–1222. 10.1016/S0140-6736(22)01586-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Xu X., Sun D., Cao M., Zhang W., Pu Y., Chen C., et al. (2022a). Analysis of clinical characteristics and prognosis of 4 264 patients with asymptomatic and mild novel coronavirus infections in Shanghai. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 34, 449–453. 10.3760/cma.j.cn121430-20220516-00490 [DOI] [PubMed] [Google Scholar]
  37. Xu X., Zhang W., Wu X., Sun Y., Yang H., Pu Y., et al. (2022b). The effectiveness and safety of chaiqin qingning capsule in upper respiratory tract infections with fever: A prospective, double-blinded, randomized, multicenter controlled trial. Complement. Ther. Med. 68, 102840. 10.1016/j.ctim.2022.102840 [DOI] [PubMed] [Google Scholar]
  38. Xu X., Zhou S., Chen C., Li J., Wu H., Jin G., et al. (2023). Efficacy and safety of reyanning mixture in patients infected with SARS-CoV-2 omicron variant: A prospective, open-label, randomized controlled trial. Phytomedicine 108, 154514. 10.1016/j.phymed.2022.154514 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Yang M., Dang S., Huang S., Li Y., Guo Y. (2020a). Multi-center clinical observation of reyanning mixture in treatment of COVID-19. Chin. J. Exp. Traditional Med. Formulae 26, 7–12. 10.13422/j.cnki.syfjx.20201321 [DOI] [Google Scholar]
  40. Yang Y., Islam M. S., Wang J., Li Y., Chen X. (2020b). Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective. Int. J. Biol. Sci. 16, 1708–1717. 10.7150/ijbs.45538 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Zhang L., Li Q., Liang Z., Li T., Liu S., Cui Q., et al. (2022a). The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg. Microbes Infect. 11, 1–5. 10.1080/22221751.2021.2017757 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Zhang L., Ma Y., Shi N., Tong L., Liu S., Ji X., et al. (2022b). Effect of Qingfei Paidu decoction combined with western medicine treatments for COVID-19: A systematic review and meta-analysis. Phytomedicine 102, 154166. 10.1016/j.phymed.2022.154166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Zhang X., Xue Y., Chen X., Wu J. M., Su Z. J., Sun M., et al. (2021). Effects of tanreqing capsule on the negative conversion time of nucleic acid in patients with COVID-19: A retrospective cohort study. J. Integr. Med. 19, 36–41. 10.1016/j.joim.2020.10.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Zhang X., Zhang W., Chen S. (2022c). Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet 399, 2011–2012. 10.1016/S0140-6736(22)00838-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Zhong L. L., Wong Y. P., Leung C. Y., Peng B., Lin Z. X., Wong Taam V. C., et al. (2022). Effects of Chinese medicine for COVID-19 rehabilitation: A multicenter observational study. Chin. Med. 17, 99. 10.1186/s13020-022-00654-z [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (1.7MB, docx)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES